19914564
2010 Jan
Hepatocellular carcinoma is among the most common solid tumors, ranking behind only lung and gastric for cancer-related deaths worldwide. Despite improved surveillance programs in many countries, most patients present with advanced-stage cancer and chronic hepatic dysfunction limiting the available treatment options. This article reviews the most pertinent randomized controlled trials with respect to surgical and adjuvant interventions that shape the current treatment algorithm for hepatocellular carcinoma.

